1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Starpharma Holdings Limited

Starpharma Holdings Limited

0.47
AUD
-0.01
(-2.08%)
-0.02EPS
294.65MMarket Cap
Mar 02Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
0.01
0.01
0.01
- -
0.02
- -
0.01
0.01
0.02
0.01
0.03
Basic EPS, GAAP
-0.05
-0.06
-0.06
0.02
-0.03
-0.04
-0.04
-0.05
-0.04
-0.04
-0.02
-0.02
-0.02
Free Cash Flow per Basic Share
-0.03
-0.04
-0.05
-0.05
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.11
0.11
0.13
0.16
0.14
0.11
0.08
0.15
0.12
0.08
0.07
0.04
0.03
Tangible Book Value per Share
0.09
0.09
0.11
0.16
0.14
0.11
0.08
0.15
0.12
0.08
0.07
0.04
0.03
Basic Weighted Avg Shares
292
318
354
378
380
381
382
407
418
420
422
428
431
Sales/Revenue/Turnover
- -
1
4
3
4
2
6
2
5
3
8
5
12
Operating Margin (%)
-6,118.68
-2,619.28
-638.22
-560.13
-308
-946.15
-276.33
-1,243.33
-378.3
-620.48
-129.65
-244.26
-74.64
Depreciation Expense
1
1
1
1
- -
- -
1
1
1
1
1
1
1
Net Income, GAAP
-15
-19
-23
8
-10
-14
-15
-20
-16
-16
-8
-10
-7
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-5,360.81
-2,356.97
-592.81
274.06
-269.81
-863.36
-243.3
-1,097.44
-345.02
-532.09
-98.5
-203.38
-61.95
Working Capital
25
28
41
60
52
41
30
60
50
33
26
17
12
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
7
3
2
1
- -
Total Equity
33
38
49
61
53
42
31
62
48
35
28
19
14
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-37.09
-53.75
-52.14
14.85
-18
-29.8
-39.82
-42.15
-29.19
-37.59
-25.95
-42.41
-45.55

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.65%
-25.91%
-27.49%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-35.76%
-14.41%
-25.28%
Sales/Revenue/Turnover
55.39%
81.96%
145.32%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
8
2025
- -
- -
5
2026
- -
- -
12

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.02
2025
- -
- -
-0.02
2026
- -
- -
-0.02

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Cheryl Maley
Full Time Employees
50
Sector
Health technology
Industry
Pharmaceuticals: major
Address
4-6 Southampton Crescent Abbotsford VIC Australia 3067
IPO Date
Aug 28, 2000
Website
starpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Starpharma Holdings Limited (SPL.AX) develops and commercializes dendrimer nanotechnology platforms for applications in pharmaceuticals, antiviral treatments, and agricultural technologies. The company offers core products and services including VivaGel, a non-hormonal vaginal microbicide for bacterial vaginosis treatment; dendrimer-based antiviral gels and coatings for preventing HIV, herpes, and influenza transmission; and targeted drug delivery systems using Priostar dendrimers for oncology and other therapeutics; as well as agricultural solutions like AgroStar dendrimers for enhanced crop protection and delivery of active ingredients. Starpharma operates primarily in the biotechnology and nanotechnology sectors, targeting pharmaceutical companies, healthcare providers, and agribusinesses across Australia, the United States, Europe, and Asia-Pacific regions. Founded in 1996 and headquartered in Melbourne, Australia, the company maintains strategic partnerships with global firms such as GSK and Janssen for product development and commercialization, with no major subsidiaries or parent relationships publicly noted. In recent developments within the last two years, Starpharma expanded its antiviral portfolio through clinical advancements in dendrimer nasal sprays for COVID-19 prevention and secured new licensing agreements for VivaGel in additional international markets, alongside ongoing funding from government grants and investor rounds to support Phase III trials and manufacturing scale-up.

Company News

Company News APIChatGPT

  • defenseworld.net

    Starpharma (OTCMKTS:SPHRY) Stock Price Down 13.7% – Time to Sell?

  • feeds.newsfilecorp.com

    Edison Issues Report on Starpharma (SPL)

  • prnewswire.com

    US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments

  • seekingalpha.com

    Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma

  • seekingalpha.com

    Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack

  • seekingalpha.com

    Starpharma Up With News, Down With None; Timing Entry Makes Sense

  • prnewswire.com

    Starpharma signs DEP® ADC Research Agreement with MSD

  • seekingalpha.com

    Starpharma Viraleze: COVID-19 Nasal Spray Development